Partner Headlines - BMY

  1. Gilead Q2 Earnings Soar As HCV Shines, HIV Rebounds

    IBD
  2. Pfizer, Merck Beat Q2 Views; Sanofi Makes PD-1 Deal

    IBD
  3. Biogen's Big-Volume Plunge Marks End Of 5-Year Run

    IBD
  4. Valeant Posts Princely Gains

    IBD
  5. Bristol-Myers Q2 profit jumps

    IBD
  6. 3 Big-Cap Drugmakers Who Beat Q2 Earnings Estimates

    IBD
  7. Shire Lifts 2015 Guidance On Strong Drug Pipeline

    IBD
  8. Lilly, Bristol-Myers Beat Q2 Views, Lift Guidance

    IBD
  9. Valeant Earnings Soar On M&A, Organic Sales Growth

    IBD
  10. Bristol-Myers Squibb Posts Upbeat Q2 Results, Lifts Profit Forecast

    Benzinga
  11. Stock Futures Up, But Volatile; SanDisk, Cirrus, Fortinet Soar

    IBD
  12. US Stock Futures Rise Ahead Of General Motors, McDonald's Earnings

    Benzinga
  13. European Medicines Agency Validates Two Parallel Type II Variation ...

    Benzinga
  14. Bristol Myers Announces EMA Validates Two Parallel Type II Variation ...

    Benzinga
  15. Earnings Scheduled For July 23, 2015

    Benzinga
  16. Second-Generation Investigational HIV-1 Maturation Inhibitor ...

    Benzinga
  17. Ethical-Drug Firms Horizon Pharma, Bristol-Myers Rally

    IBD
  18. Bristol-Myers: kidney drug win

    IBD
  19. Bristol-Myers Announces European Commission Has Approved Nivolumab ...

    Benzinga
  20. Bristol-Myers, Exelixis Drugs Score Vs. Kidney Cancer

    IBD
  21. 6 Big-Cap Drugmakers Reporting Earnings Next Week

    IBD
  22. Bristol-Myers' HIV-1 Drug Approved In Europe

    Benzinga
  23. What Will Gilead Buy Next? 4 Possible Targets

    IBD
  24. CNBC's Meg Tirrel Speculates About Gilead's New Acquisiton

    Benzinga
  25. Fast Money Picks For July 7

    Benzinga
  26. Biogen, AGTC Link Up To Develop Gene Therapy

    IBD
  27. Can Hepatitis B Be A Blockbuster Bug?

    IBD
  28. Amgen Among 3 Medical Giants With Healthy Payouts

    IBD
  29. Will Bill Ackman Go After Express Scripts Next?

    GuruFocus
  30. Fast Money Picks For June 30

    Benzinga
  31. Aetna Said Close To Humana Deal; Kroger Ups Dividend

    IBD
  32. Bristol-Myers Squibb Takes A Step Up On Cancer Drugs, But The ...

    GuruFocus
  33. Benzinga's Top Initiations

    Benzinga
  34. Piper Jaffray Initiates Bristol-Myers Squibb With Underperform

    Benzinga
  35. Axovant Sciences Sets 20-Year Record For Biotech IPOs

    IBD
  36. What We Don't Know About Antibiotics Could Kill Us

    FoxBusiness
  37. 2 M&A Rumors Moving The Market

    Benzinga
  38. ImmunoGen Surprises, PD-1 Drugs Under Scrutiny At ASCO

    IBD
  39. Stocks Protect Solid Gains; Bullish Setup For Zebra Technologies

    IBD
  40. Stocks Eke Out Narrow Gains; eBay Breakout Gains Traction

    IBD
  41. Options Outlook: Market Switches From 'Headline' To 'Sentiment' ...

    Benzinga
  42. 4 Stocks Rising On ASCO Cancer Drug News

    IBD
  43. Stocks Step Out To Mixed Start; Bristol Myers Rises, Wynn Fades

    IBD
  44. Bristol Dives On Cancer Drug

    IBD
  45. Stocks End On A Downer; Oil Jumps, Selling Resumes In Chipotle

    IBD
  46. Bristol Sinks On Lung Cancer Data; Merck Up On 2 Trials

    IBD
  47. Fast Money Picks For May 27

    Benzinga
  48. Merck got EU's CHMP

    IBD
  49. Puma Crashes, Roche Rises On Cancer Data News

    IBD
  50. Berenberg Initiates Bristol-Myers Squibb With Hold

    Benzinga
  51. Benzinga's Top Initiations

    Benzinga
  52. Benzinga's Top #PreMarket Losers

    Benzinga
  53. Bristol-Myers Squibb to Present Data at 2015 American Society ...

    Benzinga
  54. Making Money With Charles Payne: 05/8/15

    FoxBusiness
  55. Bayer Enters Into Collaboration With Isis For Enhancing Its Drug ...

    GuruFocus
  56. Merck's Stock Price, Dividend Yield Beating S&P 500

    IBD
  57. Bristol-Myers Squibb

    IBD
  58. Vanguard Adds to Four of Its Largest Stakes

    GuruFocus
  59. Merck Jumps, United Therapeutics Drops On Q1 Earnings

    IBD
  60. Merck Up On Q1, Januvia Report; Bristol, Pfizer Mixed

    IBD
  61. Stock Futures Mixed, Nasdaq Up; Apple, Vasco, Merck Rising

    IBD
  62. Earnings Scheduled For April 28, 2015

    Benzinga
  63. Nasdaq Leads Market Lower As Medical Stocks Tumble

    IBD
  64. 4 Drug Giants Reporting Earnings This Week

    IBD
  65. Benzinga's Weekend M&A Chatter

    Benzinga
  66. U.S. Tech, Dollar & Health Care ETFs To Watch This Week

    Benzinga
  67. Benzinga's Top Upgrades

    Benzinga
  68. Cancer Drugs Impress Again

    IBD
  69. CAR-T Therapy Stocks Hit Hard Following AACR Data

    Benzinga
  70. Bristol, Merck Cancer Drugs Strut Their Stuff

    IBD
  71. Bristol-Myers scores again

    IBD
  72. It's A Big Weekend For Biotech

    Benzinga
  73. Bristol's Opdivo Scores Again Against Lung Cancer

    IBD
  74. Bristol's Opdivo Scores Again Against Lung Cancer

    IBD
  75. Bristol-Myers Up Big After Drug Study Stopped Early

    Benzinga
  76. AstraZeneca's Onglyza Ups Risk Of Death, FDA Says

    IBD
  77. Benzinga's M&A Chatter for Monday April 13, 2015

    Benzinga
  78. Bristol-Myers Squibb Canada Announces Hepatitis C Cure Rate of ...

    Benzinga
  79. UPDATE: USDA Approves Supplimental Biologics License

    Benzinga
  80. USDA Accepts Supplemental Biologics License Application for Yervoy ...

    Benzinga
  81. Bristol Myers Reports Data Supporting Clinical Development Of ...

    Benzinga
  82. Biotech Pharmacyclics Spikes On Buyout Rumors

    IBD
  83. Bristol-Myers Squibb Launches Phase III Trial Of HIV Drug

    Benzinga
  84. Lannett Joins Big-Game Hunt For Drugmaker Acquisitions

    IBD
  85. Bristol-Myers goes for the gut

    IBD
  86. Drugmaker Mylan Takes Part In Pharma Feeding Frenzy

    IBD
  87. Biocept (BIOC) Soars on Liquid Biopsy Appreciation, Rigel Pharmaceuticals ...

    GuruFocus
  88. Pharma M&A: Bristol-Myers, Valeant Make Deals

    IBD
  89. Morning Market Gainers

    Benzinga
  90. Evercore ISI Technical Analysis: The 'Single Best Idea'

    Benzinga
  91. Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative ...

    Benzinga
  92. Strong Dollar Weakens Views

    IBD
  93. Drugmakers Warn On Dollar

    IBD
  94. Strong Dollar Pins U.S. Corporate Earnings Outlook

    IBD
  95. Drug Firms Report Good Q4, But Outlook Cloudy

    IBD
  96. Strong Dollar Means Flabby Outlook For Some Overseas

    IBD
  97. Bristol, Pfizer, Novartis Forecasts Face FX Pressures

    IBD
  98. Tuesday Morning Movers: Microsoft, Procter & Gamble Tumble Following ...

    Benzinga
  99. UPDATE: Bristol-Meyers Squibb Posts Upbeat Q4 Results, Issues ...

    Benzinga
  100. Earnings Scheduled For January 27, 2015

    Benzinga
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!